Related Experiment Video
Updated: Apr 30, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Pedigree and Functional Analysis of Two Cryptic OTC Variants Causing Ornithine Transcarbamylase Deficiency in Two
Qingming Wang1, Huimin Xiao2, Fang Zhang1
1Dongguan Maternal and Child Health Care Hospital, Dongguan, China.
Background:
Ornithine transcarbamylase deficiency (OTCD, MIM#311250) is a rare X-linked urea cycle disorder causing hyperammonemia. While around 600 pathogenic OTC variants have been reported, cryptic changes like synonymous or in-frame variants remain poorly characterized and are easily overlooked in routine screening.
Methods:
We analyzed the clinical and genetic profiles of two unrelated Chinese male patients clinically diagnosed with OTCD. Whole-exome sequencing (WES) was performed to identify the genetic etiology. A minigene assay was then used to assess the splicing effect of the detected synonymous variant.
Results:
WES revealed two rare OTC variants: a synonymous variant (NM_000531.6: c.663G>A, p.Lys221Lys) and a novel de novo inframe variant (c.756_761dupAGCAGC, p.Ala253_Ala254dup). Minigene assay confirmed that the c.663G>A variant causes exon 6 skipping, leading to the deletion of 41 amino acids (c.541_663del, p.Glu181_Lys221del). Both variants were classified as clinically pathogenic, and the genotype-phenotype relationships were potentially established.
Conclusion:
Our study expands the mutation spectrum of OTC and emphasizes the importance of cryptic variants interpretation and the need for additional functional studies to verify the pathogenicity of these variants.
Related Concept Videos
Translation
Translation Produces the Building Blocks of Life
Proteins are...
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

